### Cycloserine

**Indication**: Multi-drug resistant *Mycobacterium tuberculosis*  
**INN**: Cycloserine  
**Medicine type**: Chemical agent  
**List type**: Complementary (EML)  
**ICD11 code**: ML32.00

**ATC codes**: J04AB01  
**Essential medicine status**: EMLc  
**EMLc status history**:  
- First added in 1999 (TRS 895)  
- Changed in 2003 (TRS 920)  
- Changed in 2007 (TRS 950)  
- Changed in 2015 (TRS 994)  
- Changed in 2019 (TRS 1021)  
- Changed in 2021 (TRS 1035)

**Formulations**:  
- Oral > Solid: 250 mg; 125 mg (EMLc)

**Sex**: All  
**Age**: Also recommended for children  
**Therapeutic alternatives**: terizidone (ATC codes: J04AK03)

**Patent information**: Patents have expired in most jurisdictions  
[Read more about patents.](#)

**Wikipedia**: Cycloserine  
**DrugBank**: Cycloserine

---

**Summary of evidence and Expert Committee recommendations**

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended terizidone be specified as a therapeutic alternative under the square box listing for cycloserine on the EML.